Skye Bioscience Investor Relations Material
Latest events
Q1 2025
Skye Bioscience
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Skye Bioscience Inc
Access all reports
Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutic solutions targeting the endocannabinoid system (ECS). The company's primary focus is on conditions such as obesity, chronic kidney disease, and glaucoma. Skye's portfolio includes drug candidates like nimacimab, a monoclonal antibody that acts as a CB1 receptor inhibitor, and SBI-100 Ophthalmic Emulsion, designed to reduce intraocular pressure in glaucoma patients. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
SKYE
Country
🇺🇸 United States